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Mitochondria are essential organelles involved in energy metabolism via oxidative phosphorylation. They play a vital role in diverse
biological processes such as aging and apoptosis. In humans, defects in the mitochondrial respiratory chain (MRC) are responsible for or
associated with a bewildering variety of diseases. The nematode Caenorhabditis elegans is a simple animal and a powerful genetic and
developmental model system. In this review, we discuss how the nematode model system has contributed to our understanding of
mitochondrial dynamics, of the genetics and inheritance of the mitochondrial genome, and of the consequences of nuclear and mitochondrial
DNA (mtDNA) mutations. Mitochondrial respiration is vital to energy metabolism but also to other aspects of multicellular life such as aging
and development. We anticipate that further significant contributions to our understanding of mitochondrial function in animal biology are
forthcoming with the C. elegans model system.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Mitochondrion; Caenorhabditis elegans; Mitochondrial respiratory chain; Energy metabolism; Disease; Aging; Life span1. Introduction
1.1. Mitochondria
Observations of intracellular structures that likely corre-
spond to mitochondria date back to the mid-19th century
[1]. In 1890, Altmann [2] described a cytoplasmic structure
that resembles bacteria and exists as an ‘‘elementary organ-
ism’’ living within the cell. It is now widely accepted that
the ancestors of mitochondria are eubacterial endosymbionts
that became established within a host cell [3]. The symbiotic
relationship led to the loss or transfer of genes from the
bacterium to the host genome during the course of evolution
[4].
Mitochondria are a double-membrane organelle. The
inner membrane, which forms convoluted and folded struc-
tures called cristae, encloses the matrix. The inner mem-
brane is impermeable to ions and most metabolites and is0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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mediate metabolic communication with other cellular com-
partments. The outer membrane, which is permeable to most
molecules of less than 10 kDa, is notable for its roles in
organelle biogenesis and structure.
1.2. Mitochondrial DNA (mtDNA)
mtDNA was discovered in the early 1960s [5]. To date,
over 250 metazoan mitochondrial genomes have been
sequenced. These are extremely compact; introns are absent
and only one noncoding region called the displacement loop
or D-loop is present. The D-loop region contains one of the
origins of replication and two promoters for mtDNA tran-
scription [6]. mtDNAs reside in the mitochondrial matrix
attached to the inner membrane and are maternally inherited
[7]. All mammalian mtDNAs are circular double-stranded
DNA molecules of 15 to 18 kb in length encoding only 13
proteins, all subunits of the mitochondrial respiratory chain
(MRC). Two ribosomal RNAs (12S rRNA and 16S rRNA)
and 22 transfer RNAs necessary for mitochondrial trans-
lation are also encoded. The remainder of the approximately
1000 mitochondrial proteins are nuclear-encoded and are
imported into the organelle.ed.
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The primary function of mitochondria is to generate
ATP via oxidative phosphorylation, the major source of
cellular energy for most eucaryotic cells. The MRC, located
in the inner membrane, is composed of four electron
transporting protein complexes: complex I (NADH–ubiq-
uinone oxidoreductase), complex II (succinate–ubiquinone
oxidoreductase), complex III (ubiquinol–cytochrome c
oxidoreductase), and complex IV (cytochrome c oxidase)
(Fig. 1). The oxidation of the substrates, NADH or succi-
nate, coupled to the reduction of oxygen is accompanied by
the generation of an electrochemical proton gradient across
the inner membrane. A fifth protein, complex V (ATP
synthase or the F0F1-ATPase) uses this proton gradient to
drive ATP synthesis. Coenzyme Q or ubiquinone (Q) is an
essential, lipophilic carrier needed to shuttle electrons
between complexes I or II to complex III. Cytochrome c
(cyt c) is a water-soluble heme-containing protein that
mediates electron passage between complexes III and IV
(Fig. 1).
1.4. Other roles of mitochondria
By the 1970s, substantial progress had been achieved in
understanding the biochemical roles of mitochondria. In
addition to being the site of respiration and oxidative
phosphorylation, mitochondria are also involved in several
other important functions such as heme, lipid, and amino
acid biosynthesis, the Krebs cycle, the urea cycle, fatty acid
oxidation, and ion homeostasis [8]. However, the contribu-
tions of mitochondria to organismal development and inher-
itance have been only recently appreciated. The first
mitochondrial disease was described in 1962 [9] but it
would take another 26 years for the identification of a
mutation in a mitochondrial disease [10,11]. Since then,
the field of mitochondrial medicine has experienced rapidFig. 1. The mitochondrial respiratory chain. The five complexes of the MRC (I–V
IV translocate H+ to the cytosolic side (top) of the inner membrane. Complex Vgrowth and hundreds of mutations affecting nuclear- or
mtDNA-encoded MRC genes have now been identified.
The clinical manifestations of mitochondrial diseases can be
diverse and bewildering [12]. Mitochondria have been
associated with aging [12,13], with neurodegenerative con-
ditions such as Alzheimer’s [14], Parkinson’s [15], and
Huntington’s diseases [16], and with cancer, such as heredi-
tary paraganglioma [17–19]. Mitochondria are also inti-
mately involved in apoptosis or programmed cell death, but
other reviews have addressed this area [20–22].
1.5. Caenorhabditis elegans and mitochondria
C. elegans is a small, free-living nematode found in the
soil. In the 1960s, Brenner [23] selected it as a simple model
for his intensive studies of the genetics and development of
the nervous system. We now understand more about the
biology of C. elegans than of many other eucaryotes. Its life
cycle is complex but short, taking about 3 days to complete
at 25 jC [24]. A single self-fertilized adult hermaphrodite is
capable of producing 300 progeny. Each embryo will
develop, hatch, and proceed through four larval stages
(L1–L4) before becoming an adult [24]. Under food dep-
rivation or stress, an alternative developmental path, called
the dauer larva, can be launched. Dauer larvae can survive
for months in this stage and, in response to more favorable
growth conditions, can exit dauer to resume maturation to
the adult [25]. The adult C. elegans hermaphrodite is
anatomically simple with only 959 somatic cells and yet
contains multiple, highly differentiated tissue types such as
neurons, muscles, intestine, and epidermis [26]. The nem-
atode’s transparency has allowed a complete microscopic
description of its invariant cell lineage [27,28].
A number of human disease genes have homologs in the
nematode, and the nematode system has already yielded
important insights into the function of some of these
[29,30]. The availability of the complete mtDNA and) are localized to the mitochondrial inner membrane. Complexes I, III, and
uses the proton gradient to synthesize ATP in the matrix (bottom).
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gene function using forward and reverse genetic approaches
[31,32]. The construction of the physical map and its
alignment to the genetic map eases the molecular analysis
of mutations (http://www.wormbase.org, WS93 release,
December 20, 2002). Specific loss-of-function phenocopies
that offer a quick and easy way to study the relationship
between genotype and phenotype can be produced exper-
imentally by a phenomenon known as RNA interference, or
RNAi [33]. The introduction of cloned genomic DNA
fragments by microinjection into mutants to rescue their
phenotype is also a powerful genetic tool [34].
The structure, metabolism, and bioenergetics of the
nematode MRC are very similar to the mammalian counter-
part [35]. Many pathways of intermediary metabolism,
including the Krebs cycle, are also conserved in C. elegans
[36,37]. In 1992, Okimoto et al. [31] sequenced the nem-
atode mtDNA, which turned out to be slightly smaller than
its human counterpart, missing the ATP8 gene and having a
different gene organization and transcriptional pattern. The
12 mtDNA-encoded MRC polypeptides are highly con-
served among eucaryotes (Table 1). A survey of the C.
elegans nuclear genome reveals that the majority of mam-
malian nuclear-encoded MRC genes are also highly con-
served (Table 1).
The conservation of mitochondrial function and the
many technological and anatomical advantages offered by
the nematode will contribute to our understanding of mito-
chondria in the life of complex organisms. In the following
sections, we discuss a number of recent findings that high-
light the importance of mitochondrial function in the nem-
atode (Fig. 2).2. Mitochondrial dynamics and genetics
2.1. Mitochondrial distribution and division
Mitochondria can be very dynamic structures capable of
forming reticular or tubular networks [38]. They can coloc-
alize and interact with certain cytoskeletal components [39],
thus providing the first clues to the mechanisms of their
distribution and movement. These interactions may serve to
localize mitochondria to regions where there is an active
demand for energy such as the synapses of neurons [40,41].
The distribution and positioning of mitochondria in the
nematode is also regulated. In 1982, a mutation in the anc-1
(anchorage of nuclei abnormal) gene of C. elegans was
found to cause mis-anchoring of nuclei and mitochondria in
the hypodermis, allowing these organelles to float freely in
the cytoplasm of syncytial cells [42]. The mitochondria
were mostly spherical as opposed to tubular in shape and
often clustered. Recently, the anc-1 gene was cloned and
was found to encode a protein consisting of several large
coiled regions, a nuclear envelope localization domain, and
an actin-binding domain [43]. ANC-1 may thus connectnuclei and mitochondria to the actin cytoskeleton and the
nuclear envelope. It remains to be determined whether the
anchoring machinery is shared by different organelles or
whether the disruption of nuclear positioning indirectly
affects the distribution of mitochondria.
Mitochondrial division is required to regulate organelle
numbers during cell division, cell differentiation, or in
response to environmental changes. A role for mitochondrial
fusion is more elusive. Labrousse et al. [44] identified the C.
elegans dynamin-related protein, DRP-1, which affects both
mitochondrial distribution and division. DRP-1 belongs to
the dynamin family of proteins and has a characteristic N-
terminal GTPase domain, a middle domain, and a C-terminal
assembly domain that mediates protein–protein interactions
[45]. RNAi of C. elegans drp-1 causes embryonic lethality
and abnormal morphology and distribution of mitochondria,
consistent with a role for drp-1 in mitochondrial segregation
[44]. Using various dominant negative drp-1 mutations, it
was shown that the protein is involved in the scission of the
mitochondrial outer membrane while the inner membrane is
unaffected, suggesting that mitochondrial division comprises
two independent events. Overexpression of wild-type DRP-1
enhances the rate of division and mitochondrial fragmenta-
tion. Time-lapse photography reveals that DRP-1 is localized
in spots where mitochondrial severing occurs and disappears
after division, consistent with a role in division. DRP-1 may
participate directly in the fission process or it may do so by
recruiting other molecules of a scission machinery. DRP-1
may also serve to tether dividing mitochondria to specific
locations within a cell by interacting with components of the
cytoskeleton. It will be interesting to determine whether
DRP-1 activity is adjusted to accommodate variable rates
of cell division during growth.
2.2. Mitochondria and mtDNA copy number
The abundance of mitochondria in a cell as well as its
mtDNA content are generally believed to be related to the
energy requirements of that cell [46,47], but the precise
relationships between these parameters remain obscure. Yet,
the numbers of mitochondria and mitochondrial genomes in
a cell are regulated [47] and can vary substantially between
tissues.
Recently, we performed a comprehensive investigation of
the developmental regulation of mitochondrial genome copy
number in C. elegans [48]. The mtDNA copy number of a
wild-type embryo is f 2.5 104 and remains unchanged
through the early stages of development and into the L3
stage. It increases fivefold to 1.3 105 in the L4 stage and a
further sixfold to 7.8 105 in the adult stage. The copy
number increases coincide with sexual maturation; sperma-
togenesis begins at the early L4 stage while oogenesis
begins in the young adult.
mtDNA content is closely associated with reproduction.
Mutations in the germ line proliferation gene, glp-1, result in
an almost complete absence of germ line cells while somatic
Table 1
Complex Bovine Neurospora Human C. elegans Probability, P(N)a
I-FPb 51 kDa 51 kDa NDUFV1 C09H10.3 (nuo-1) 2 10 203
24 kDa 24 kDa NDUFV2 F53F4.10 110 81
9 kDa N.I.c NDUFV3 N.I. –
I-IPb 75 kDa 78 kDa NDUFS1 Y45G12B.1 3 10 225
49 kDa 49 kDa NDUFS2 T26A5.3 6 10 165
K09A9.5 (gas-1) 2 10 163
30 kDa 31 kDa NDUFS3 T10E9.7 (nuo-2) 4 10 73
23 kDa (TYKY) 23 kDa NDUFS8 T20H4.5 7 10 74
20 kDa (PSST) 19.3 kDa NDUFS7 W10D5.2 4 10 73
18 kDa (AQDQ) 21 kDa NDUFS4 ZK973.10 2 10 35
15 kDa 15 kDa NDUFS5 Y54E10134BL.5 9 10 10
13 kDa (A) 13 kDa NDUFS6 F22D6.4 2 10 20
13 kDa (B) 29.9 kDa NDUFA5 C33A12.1 110 30
I-HPb ND1 ND1 ND1 ND1 7 10 43d
ND2 ND2 ND2 ND2 8 10 6d
ND3 ND3 ND3 ND3 7 10 6d
ND4 ND4 ND4 ND4 110 48d
ND4L ND4L ND4L ND4L e
ND5 ND5 ND5 ND5 4 10 51d
ND6 ND6 ND6 ND6 e
B18 N.I. NDUFB7 D2030.4 2 10 25
SDAP (ACP) 9.5 kDa NDUFAB1 Y56A3A.19 110 30
F16B4.6 4 10 18
F37C12.3 6 10 18
B22 B22 NDUFB9 C16A3.5 3 10 21
SGDH N.I. NDUFB5 C25H3.9a 110 10
B14.7 21.3b LOC126328 N.I. –
B14.5a N.I. NDUFA7 F45H10.3 4 10 8
ESSS N.I. Q8WZ96 N.I. –
Q9NX14
19 kDa (PGIV) 20.8 kDa NDUFA8 Y54F10AM.5 2 10 17
MLRQ N.I. NDUFA4 N.I. –
MWFE 9.8 kDa NDUFA1 N.I. –
KFYI N.I. NDUFC1 N.I. –
B17 N.I. NDUFB6 N.I. –
B12 N.I. NDUFB3 C18E9.4 4 10 5
B8 10.5 kDa NDUFA2 Y63D3A.7 110 18
C25A1.13 110 8
MNLL N.I. NDUFB1 N.I. –
B14.5b N.I. NDUFC2 Y71H2AM.4 4 10 5
B9 9.5 kDa NDUFA3 N.I. –
42 kDa N.I. NDUFA10 K04G7.4a 7 10 33
K04G7.4b 3 10 5
AGGG N.I. NDUFB2 F44G4.2 9 10 8
ASHI N.I. NDUFB8 Y51H1A.3a 2 10 13
Y51H1A.3b 2 10 13
PDSW 12.3 kDa NDUFB10 F59C6.5 2 10 18
B15 N.I. NDUFB4 N.I. –
B14 14.8 kDa NDUFA6 Y57G11C.12 7 10 12
39 kDa 40 kDa NDUFA9 Y53G8AL.2 5 10 51
B17.2 B17.2 DAP13 Y94H6A.8 8 10 27
B16.6 N.I. GRIM19 C34B2.8 110 15
II FP SDH1 SDHA C03G5.1 2 10 252
C34B2.7 110 247
F48E8.3 (Fumarate reductase) 110 14
IP N.I. SDHB F42A8.2 110 94
CII-3 (QPS1) N.I. SDHC T07C4.7 (mev-1) 2 10 18
CII-4 (QPS2) N.I. SDHD F33A8.5 110 15
III I I UQCRC1 ZC410.2 8 10 92
F56D2.1 8 10 84
II II UQCRC2 T10B10.2 5 10 43
T24C4.1 3 10 37
III (Cyt b) Cyt b CYB Cyt b (ctb-1) 7 10 86d
IV (Cyt c1) Cyt c1 CYC1 C54G4.8 (cyc-1) 2 10 72
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Table 1 (continued )
Complex Bovine Neurospora Human C. elegans Probability, P(N)a
III V (RISP) RISP UQCRFS1 F42G8.12 (isp-1) 2 10 58
VI (14 kDa) N.I. UQCRB T02H6.11 3 10 13
VII (9.5 kDa) VII UQCRQ F45H10.2 2 10 10
R07E4.3 2 10 10
VIII (9.2 kDa) VIII UQCRH T27E9.2 9 10 12
IX (8.0 kDa) N.I. N.I. N.I. –
X (7.2 kDa) N.I. UQCR10 N.I. –
XI (6.4 kDa) N.I. 6.4 kDa N.I. –
IV I (COI) COI COI COI 110 180d
II (COII) COII COII COII 9 10 41d
III (COIII) COIII COIII COIII 9 10 62d
IV V COX4I1 W09C5.8 2 10 14
COX4I2
Va VI COX5A Y37D8A.14 2 10 27
Vb IV COX5B F26E4.9 (cco-1) 6 10 13
VIa N.I. COX6A1 F54D8.2 6 10 15
COX6A2
VIb N.I. COX6B Y71H2AM.5 5 10 16
VIc N.I. COX6C N.I. –
VIIa N.I. COX7A1 N.I. –
COX7A2
VIIb N.I. COX7B N.I. –
VIIc N.I. COX7C F26E4.6 110 7
VIII N.I. COX8 N.I. –
V-F0 a a ATP6 ATP6 110 7d
b b ATP5F1 F02E8.1 3 10 11
F35G12.10 3 10 9
c c ATP5G3 Y82E9BR.3 110 32
d N.I. ATP5H C06H2.1 3 10 8
e N.I. ATP5I R04F11.2 110 5
f N.I. ATP5J2 R53.4 110 8
g N.I. ATP5L C53B7.4 7 10 12
K07H12.3 7 10 12
F6 N.I. ATP5J N.I. –
A6L 8 ATP8 N.I. –
OSCP ATP5 ATP5O F27C1.7 (atp-3) 4 10 37
IF1 N.I. ATPI B0546.1 4 10 15
K10B3.9 5 10 12
V-F1 a a ATP5A1 H28O16.1 6 10 226
h h ATP5B C34E10.6 (atp-2) 110 219
g N.I. ATP5C1 Y69A2AR.18a 110 82
Y69A2AR.18b 7 10 62
y y ATP5D F58F12.1 110 33
q q ATP5E R05D3.6 2 10 5
ZC262.5 2 10 5
F32D1.2 5 10 5
a Human protein sequences were blasted against the C. elegans Wormpep database (WS93 release, December 20, 2002) from WormBase (http://
www.wormbase.org). A dash (– ) indicates that no sequence of significant homology ( P(N)>10 4) is found in the C. elegans genome.
b Bovine complex I can be fragmented with the chaotropic ion, perchlorate, into soluble flavoprotein (FP) and iron–sulfur (IP) fragments, and an insoluble
hydrophobic (HP) fragment.
c N.I., not identified.
d Human protein sequences were blasted against the SWISS-PROT database (Version 40.33, November 9, 2002) from European Bioinformatics Institute
(http://www.ebi.ac.uk/index.html).
e These nematode proteins were identified from hydropathy profile comparisons with the corresponding mouse and D. yakuba proteins. See Ref. [31] for
details.
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the Notch family of transmembrane receptor proteins and
regulates the mitotic division of germ cells. Germ cells are
few in number in a young larvae but proliferation becomes
significant after the L3 stage. The mtDNA copy number of
an L4-stage glp-1 animal is about 7.0 104, which is abouthalf of a wild-type L4 [48]. The glp-1 animal does not show a
further copy number increase upon developing to the adult.
We have concluded that the increase in mtDNA copy number
observed in the wild type during development from the L3 to
the adult stages has two components: a somatic component,
which is glp-1 independent, occurs between the L3
Fig. 2. The role of mitochondria in the life of an eucaryote. The studied C. elegans genes whose products are involved in mitochondrial function and biogenesis
are depicted.
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and a glp-1 dependent, germ line-associated component
occurs between the L3 and adult stages (the difference
between f 7.0 104 and 1.3 105 occurs during develop-
ment to L4 and the increase from 1.3 105 to 7.8 105
occurs during development to the adult).
The majority of the mtDNA copy number increase
associated with the germ line is related to the production
of oocytes [48]. The feminization or fem genes are needed
during spermatogenesis in both males and hermaphrodites.
A loss-of-function fem-1 mutation blocks sperm production
in the hermaphrodite while oocyte production remains
unaffected [50]. In contrast, a gain-of-function fem-3 muta-
tion blocks oocyte production and results in excess sperm in
the hermaphrodite germline [51]. The mtDNA copy num-
bers in a fem-1 L4 (1.4 105) and in a fem-1 adult
(8.0 105) are comparable to the wild type situation. The
mtDNA copy numbers of fem-3 mutants show a markedly
different profile; the fem-3 L4 (1.7 105) resembles the
wild type, but its mtDNA content increases little in the adult
(1.9 105), suggesting that the majority of the organellar
genomes are associated with the production of oocytes. In
fact, the mtDNA copy numbers of the fem-1 oocyte
(1.8 104), the wild type embryo (2.5 104), and the first
three larval stages are similar. The mtDNA inherited
through the oocyte supports the early developmental steps.
Sperm production contributes little to the mtDNA content of
the germ line.
The mtDNA content of C. elegans cells is considerably
lower than the estimated values of 103 to 104 in most higher
eucaryotic cells. C. elegans has an invariant cell lineage; the
L1 and L4 larvae have about 560 and 1000 somatic cell
nuclei, respectively. The f 2.5 104 copies of mtDNA in
the wild-type L1 and the f 7.0 104 copies in the germ line
deficient L4 correspond to averages of f 45 to f 70
mtDNA per somatic cell. It remains to be determinedwhether different somatic cells or tissues have distinct
mtDNA copy numbers. For instance, tissues that are highly
oxidative, such as muscles and neurons, might be expected to
carry more mitochondria and mtDNAs. We have estimated
that undifferentiated germ line cells and sperm have f 250
and 30–40 copies of mtDNA, respectively. Does the low
organellar genome content of the nematode reflect a dimin-
ished role for mitochondrial energy generation because of
the hypoxic environment of the soil where it is normally
found?
How the number of mitochondria changes during the
course of nematode development has not been investigated.
In normal somatic tissues, the number of mitochondria, the
number of mtDNA copies, and the respiratory capacity of a
cell correlate loosely with one another [47,52,53]. The
correlation no longer holds in transformed cells [54] or in
cells with mitochondrial dysfunction [55–57]. The increases
in mtDNA copy numbers during nematode maturation are
suggestive of a parallel increase in the number of organelles,
although this has not been documented. Interestingly,
increases in mitochondrial number and in the frequency of
mitochondrial division upon shifting the temperature from
15 to 25 jC have been observed [44]. The increased number
of organelles may represent an adaptation to higher meta-
bolic activities. Consistent with this idea, oxygen consump-
tion rates [58] and ubiquinone (Q9) contents of young adults
[59] are doubled with such a temperature shift. It remains to
be determined whether mtDNA content also changes with
temperature.
2.3. mtDNA inheritance, transmission, and maintenance
Mitochondrial genetics differs from nuclear genetics in
three aspects. First, nuclear genes follow a Mendelian
pattern of inheritance, whereas mitochondrial genes are
maternally inherited [60]. Second, the nuclear genome is
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is polyploid. Normally, only one form of mtDNA is present;
this is a state called homoplasmy. Occasionally, two or more
forms of mtDNA coexist within a cell in a state termed
heteroplasmy, which is often associated with mtDNA muta-
tions [61]. Third, unlike a diploid nuclear gene that can
assume three states (homozygous wild type, heterozygous,
homozygous mutant), mtDNA heteroplasmy does not vary
by discrete steps. The proportion of mutant mtDNAs can
vary, increasing or decreasing by mitotic segregation as cells
divide [62]. The factors controlling heteroplasmy are poorly
understood but are under investigation [63].
Several observations suggest that the presence of mtDNA
mutations is related to the aging process and to oxidative
stress. The first deletions in the nematode mitochondrial
genome were detected in an aging, wild-type population
[64,65]. The deletions arose spontaneously and their fre-
quency increased with age. Similarly, a wide array of
mtDNA rearrangements had been detected in the skeletal
muscle of elderly people [66]. Interestingly, the C. elegans
age-1 (ageing abnormal) mutant, which is more resistant to
oxidative stress and lives twice as long as the wild type,
exhibits a small but significantly lower rate of mtDNA
deletions [65]. It is not certain whether these mtDNA
deletions reduce the carrier’s fitness or whether they can
be transmitted to the next generation.
A direct estimate of the nematode mtDNA mutation rate
was obtained using a series of mutation accumulation lines
maintained by single-progeny descent for over 200 gener-
ations [67]. There were 16 base substitution and 10 inser-
tion–deletion mutations detected in over 770,000 bp of
sequenced DNA, corresponding to a measured rate of
mutation approximately 100-fold higher than previous indi-
rect estimates. Four of the insertion–deletion mutations
were predicted to introduce drastic changes to coding
sequences; all four are homoplasmic or nearly so for the
mutated genomes and have modest but significant reduc-
tions in fitness.
mtDNA inheritance and maintenance are most poorly
understood for the heteroplasmic condition. The mater-
nally inherited uaDf5 mutation in the C. elegans mtDNA
is a large-scale deletion that removes a total of 11 genes,
including genes for four MRC subunits and seven tRNA
genes [68]. The mutation has been maintained in a stable
heteroplasmy for over 100 generations in the absence of
selection without the appearance of homoplasmic wild-
type or mutant animals. While individual animals have
between f20% and f 80% uaDf5 mtDNA, the popula-
tion average is f 60% and does not change as the animals
develop. We have not observed any phenotype associated
with the deletion. The stability of the heteroplasmic con-
dition suggests that the mutated and wild-type mtDNAs do
not segregate from each other. Stable heteroplasmy has also
been observed in cybrids [69] and in a Drosophila subobs-
cura mtDNA deletion mutant [70]. The D. subobscura
mutation, also a large-scale deletion, shares many featureswith the uaDf5 line including a stable heteroplasmic state
ranging from 50% to 80% mutant mtDNA, the absence of
homoplasmic segregants, and the lack of a phenotype. The
stable heteroplasmy seen in worms and in D. subobscura is
in contrast to the unstable heteroplasmy seen in Holstein
cows [71] and in crosses between D. mauritiana and D.
melanogaster [72] where the segregation of mtDNA geno-
types can occur within a single generation. Unstable hetero-
plasmies may result from inter-mitochondrial heteroplasmy
(the different forms of mtDNA are present in distinct
organelles), whereas stable heteroplasmies may be intra-
mitochondrial (the mtDNAs are intermixed within an organ-
elle).
The intergenerational stability of the uaDf5 heteroplasmy
appears to be controlled by two opposing forces, one that
increases the proportion of uaDf5 mtDNA when it is low,
and a second, decreasing it when proportions are high [68].
At intermediate proportions, the forces are balanced and the
uaDf5 levels in the offspring reflect the maternal state.
Single, self-fertilized hermaphrodites with intermediate lev-
els of uaDf5 mtDNA (f 50–60%) have broods that form
random, non-skewed distributions centered on the parental
mean. However, hermaphrodites with more extreme propor-
tions of uaDf5 mtDNA (f 20% or f 80%) have broods
with skewed distributions; the proportions of uaDf5 mtDNA
in the offspring shift towards intermediate levels. The same
forces may also account for the maintenance of a stable
heteroplasmy in the D. subobscura mtDNA deletion mutant.
What are the forces involved in maintaining a stable
heteroplasmy and when do they act? It has been suggested
deletion-containing mtDNA molecules may have a replica-
tive advantage over the wild-type mtDNA molecules
because they are shorter. In the case of the uaDf5 deletion,
there does not appear to be a replicative advantage, since the
proportion of uaDf5 is constant at f 60% through develop-
ment from the L1 to the adult. This includes times of intense
mtDNA replication from L3 to adult [48]. This is in contrast
to the D. subobscura situation where an increase in hetero-
plasmy appears to correlate closely with the time of active
mtDNA replication [73]. Thus, a replicative advantage due
to size, if it exists, may be species- or even tissue-specific.
Alternatively, a respiratory advantage may account for both
forces in maintaining a stable heteroplasmic state. The wild-
type DNA may harbor an undetected mutation that would
severely affect respiratory function. If this were the case, the
uaDf5 mtDNA must be maintained to complement the
undetected lethal mutation in the ‘wild-type’ genome; both
genomes are needed to produce a fully functional MRC and
homoplasmy with either genome may be severely compro-
mising or lethal. Sequencing the ‘wild-type’ mitochondrial
genome should address this possibility. Respiratory selec-
tion against homoplasmy must operate prior to embryo-
genesis, possibly through the elimination of germ cells or
oocytes with very high or very low uaDf5 contents, since
there is no observed phenotype, including inviable embryos,
associated with the uaDf5 mutation. Elimination of cells via
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dite germ line [74].
Heteroplasmic uaDf5 animals, although without a phe-
notype, have adjusted their mitochondrial genome contents.
Both male and female animals carrying the uaDf5 deletion
have approximately twice the number of mitochondrial
genomes as their wild-type counterparts [68]. The up-
regulation of the mtDNA copy number may in part com-
pensate for the effects of the mutation by enhancing the
production of functional mitochondrial transcripts and/or
proteins. Alternatively, the compensatory increase in
mtDNA may ensure that uaDf5 animals maintain an approx-
imately normal complement of wild-type genomes, in addi-
tion to the uaDf5 molecules. This is in contrast to
cytoplasmic cybrids derived from Kearns–Sayre syndrome
cells, which harbor large deletions in their mtDNA, that
maintain a constant mass of mtDNA [75]. A parallel
increase in mtDNA content has also been reported in the
heteroplasmic D. subobscura deletion strain [55], although
this up-regulation was not observed in a backcrossed strain
with a similar level of heteroplasmy [76]. These observa-
tions suggest that mtDNA copy number regulation may
differ between organisms. Understanding the signals that
regulate mtDNA copy number and the mechanisms by
which regulation is achieved remain important challenges.3. Mitochondrial diseases
3.1. mtDNA mutations
Surprisingly, all mutations in the nematode mitochondrial
genome have had little or no effect on the carriers (see
examples in Section 2.3). Animal mtDNAs are extremely
compact with few noncoding regions and, thus, most
mutations affect a coding sequence or a region involved in
the replication or expression of the mtDNA. In contrast to
the nematode situations, over 100 pathogenic point muta-
tions and 200 insertions, deletions, or rearrangements have
been identified in the human mitochondrial genome (MITO-
MAP: A Human Mitochondrial Genome Database. http://
www.mitomap.org, 2002). Perhaps simple eucaryotes, like
the worm or the fly, can better tolerate deleterious mtDNA
mutations or have mechanisms to prevent their transmission.
It is also puzzling why mtDNA mutations have not been
reported from the large numbers of genetic screens for
mutations that affect motility, reproduction, development,
or other functions [77]. Clearly, the genetics of the mito-
chondrial genome in C. elegans still contains much to be
explored.
3.2. Nuclear mutations
For the majority of human mitochondrial diseases of
nuclear origin, the precise molecular defect is not known.
The first defect in a nuclear-encoded MRC gene, reported in1995, was a point mutation in the SDHA gene encoding the
large or flavoprotein subunit (A subunit) of succinate
dehydrogenase or complex II, which results in Leigh disease
[78]. Several pathogenic mutations in complexes I, II, and
IV have since been characterized [79]. Like mtDNA muta-
tions, the phenotypes of nuclear-encoded mutations are
diverse and tissue-specific.
With the availability of the complete genome sequence, it
is now possible to use a reverse genetic approach called
target-selected mutagenesis to identify mutations in genes of
choice [80]. The nuo-1 gene, which encodes the 51-kDa
active site subunit of the NADH-ubiquinone oxidoreductase
or complex I and contains FMN or flavin mononucleotide
and iron–sulfur cluster cofactors, is the first MRC gene to
have been targeted in this way [81]. The recovered mutation
nuo-1(ua1) is a deletion allele that has the first three of six
exons removed. It is likely a null mutation and is homo-
zygous lethal. Homozygous mutant offspring of a hetero-
zygous hermaphrodite hatches and develops through two
larval stages before arresting at the L3 stage prior to sexual
maturation. Gonad development is more severely affected
and is arrested at the earlier L2 stage. Mutant animals
exhibit a number of behavioral defects indicative of mus-
cular and/or neuronal defects, including reduced mobility,
impaired feeding, and a slower defecation cycle. Mutations
in the human nuo-1 homolog, NDUFV1 (NADH–ubiqui-
none oxidoreductase flavoprotein subunit), result in myo-
clonic epilepsy, hypotonia, ataxia, Leigh syndrome,
leukodystrophy, and other neurological conditions [82,83].
In those cases, all probable null NDUFV1 mutations coexist
with point mutations that are likely hypomorphic, suggest-
ing that the gene is also essential in humans. Similarly, the
C. elegans atp-2 gene, which encodes the ß-subunit of the
ATP synthase, has also been targeted for gene disruption
[81]. The atp-2(ua2) mutation deletes the first exon and part
of the second, completely removing the coding region for
the amino-terminal mitochondrial targeting sequence. Not
surprisingly, the atp-2(ua2) mutation is also lethal, produc-
ing a phenotype that is almost indistinguishable from the
nuo-1(ua1) mutation. The coq-3(qm188) mutation is a de-
letion in a methyltransferase-encoding gene of coenzyme Q
biosynthesis [84]. Heterozygous hermaphrodites (coq-3/+)
produce 1/4 homozygous coq-3 progeny that reach adult-
hood but are usually sterile. Those that are fertile have
extremely low brood sizes and their progeny die as L1
larvae. Interestingly, homozygous coq-3 mutants comple-
mented with a coq-3(+) transgenic array are normal, but loss
of the array produces an L2-stage arrest. In all three nuclear
mutants (nuo-1, atp-2, coq-3), a maternal effect suggests
that the mother deposits a product, perhaps mRNA, into the
oocyte, which supports development until zygotic expres-
sion can supply further needs.
The nuo-1(ua1), atp-2(ua2), and coq-3(qm188) muta-
tions indicate that a functional MRC is essential for viability
and larval development past the L3 stage. By extension,
other conditions or mutations that impair MRC function
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discussed later (refer to Sections 3.3 and 4). The f 200
proteins involved in MRC biogenesis, which include
mtDNA and nuclear DNA-encoded MRC subunits, compo-
nents of the mitochondrial import apparatus, chaperones and
assembly factors, and the mitochondrial replication, tran-
scription, and translation machinery, may also cause lethal-
ity when their genes are mutated. Two further lines of
evidence support a larval arrest phenotype for such muta-
tions. First, clk-1 (biological clock abnormal) mutations,
which disrupt the biosynthesis of ubiquinone, have a condi-
tional lethal phenotype. When grown on a ubiquinone-
deficient strain of E. coli, clk-1 mutants suffer an L2 stage
developmental arrest [85]. The L2 arrest, as judged by
gonad development, is remarkably similar to the nuo-1
and atp-2 induced arrests. Second, when MRC biogenesis
is inhibited with ethidium bromide, an inhibitor of mtDNA
replication [48], or with doxycycline or chloramphenicol,
inhibitors of mtDNA translation [81], a quantitative and
homogeneous developmental arrest as L3 larvae also results.
An L2 or L3 stage larval arrest may therefore be a common
outcome for mutations that produce MRC defects, suggest-
ing that a genetic screen using this endpoint may be a
fruitful way of isolating additional MRC gene mutations.
Why do worms with an impaired MRC arrest at the L2 or
L3 stage? We believe that maturation to the L4 stage is
associated with substantially increased energy demands.
Three observations support this notion. First, aerobic metab-
olism, as measured by oxygen consumption, peaks at the L3
and L4 stages [86]. This is consistent with an observed
decrease in activity of the glyoxylate cycle during the L1
stage and a shift towards respiration in the later larval stages
[37]. Second, the mtDNA copy number increases fivefold
between the L3 and the L4 stages [48]. Finally, the ATP-2
protein levels also increase significantly with development
to the L4 stage (W. Tsang and B. Lemire, unpublished data).
The increases in mtDNA copy number and in ATP-2 protein
contents presumably reflect active synthesis of and demand
for MRC components. The homogeneous and quantitative
developmental arrest that results when MRC biogenesis is
blocked suggests that the L3-to-L4 transition involves an
energy-sensing mechanism that invokes a developmental
checkpoint when an energy deficit arises. An energy sensor
could respond to one or more metabolites, whose concen-
trations communicate information about the status of mito-
chondrial energy production.
Recently, a number of proteins capable of sensing the
concentrations of metabolites that may reflect the mitochon-
drial energy status have been identified. The corepressor
CtBP or carboxyl-terminal binding protein is a transcrip-
tional regulator containing an NAD+/NADH binding motif
important for development and cell cycle regulation [87].
CtBP binding to its partner proteins is dramatically sensitive
to the levels of NADH, allowing it to serve as a redox
sensor. SIRT3, a homolog of silent information regulator
two or SIR2, is a conserved mitochondrial protein with aNAD+-dependent protein deacetylase activity that may
sense the organellar or cellular redox state [88]. Unfortu-
nately, the SIRT3 targets have yet to be identified, but
members of the SIR2 family of proteins are NAD+-depend-
ent histone deacetylases involved in chromosome stability,
gene silencing, and cell aging [89,90]. Provocatively, a
Salmonella enterica SIR2 homolog was recently shown to
regulate metabolism by deacetylating a posttranslationally
modified acetyl-coenzyme A synthetase, which is needed
for growth on propionate and acetate [91]. The mammalian
target of rapamycin (mTOR), which functions to regulate
ribosome biosynthesis and cell growth, is a protein kinase
that directly senses the intracellular concentration of ATP
[92]. Interestingly, mutations of the mTOR homolog in C.
elegans are lethal and result in an L3 developmental arrest
[93]. The nematode mTOR homolog may well be the
developmental or energy sensor that controls the transition
from the L3 stage to the L4 stage. Thus, a developmental
checkpoint is possibly regulated by a sensor protein that
responds to the levels of ATP and/or the ratio of NADH/
NAD+.
In addition to proteins, other molecules may act in energy
sensing. Ubiquinone, in addition to its role as an electron
carrier, functions as a signaling molecule. In E. coli,
ubiquinone is a redox signal for the Arc regulatory system
[94]. Observations with C. elegans clk-1 and coq-3 mutants
suggest a non-mitochondrial site of action for ubiquinone in
animal development. The C. elegans nuclear hormone
receptor DAF-12 (dauer larva formation abnormal) is
important for the developmental decision between repro-
ductive growth and the alternate L3 stage called the dauer
[95]. The DAF-12 ligand, a steroid hormone, is produced in
response to environmental signals, including food availabil-
ity, and may thus link development and energy production
[96].
Other mutations in nuclear-encoded C. elegans genes
(gas-1, mev-1, isp-1) have been identified in genetic screens
for particular phenotypes. Mutations in these genes do not
result in larval arrest and are discussed in Section 4.
3.3. RNAi and maternal contribution
RNAi is a process by which double-stranded RNA
(dsRNA) interferes with gene expression. RNAi was first
reported in C. elegans in 1998 and many features of the
RNAi effect have since been described [33]. The dsRNA
can be introduced by microinjection [33], by feeding the
worms with bacteria engineered to produce dsRNA [97], by
soaking the worms with a dsRNA solution [98], or by
expressing constructs with inverted repeats that form dou-
ble-stranded regions [99]. The RNAi effect is usually very
specific and phenocopies the null allele of the targeted locus
[100,101].
The RNAi technology has been applied to a number of
MRC genes and has uncovered a strong maternal effect.
When wild-type nematodes are fed with E. coli engineered
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10% and 65% of the progeny arrest as embryos after
gastrulation but prior to tissue differentiation, respectively
[81]. Recent analyses of genes on chromosomes I and III in
systematic RNAi screens have revealed that embryonic
lethality is associated with many MRC genes [102,103].
The nuo-1(RNAi) or atp-2(RNAi) phenotypes are more
severe than the corresponding null alleles, suggesting that
nuo-1(+) or atp-2(+) genes in the heterozygous hermaphro-
dite contribute to the survival of the respective homozygous
mutant offspring. A maternal contribution of mRNA or
protein supports development in the homozygous offspring
up to the L3 stage. This maternal contribution of metabolic
potential to the embryo, made evident with RNAi technol-
ogy, appears to be a conserved event for mitochondrial
genes. Mutations in the C. elegans dif-1 (differentiation
abnormal) gene have a maternal-effect, embryonic lethal
phenotype [104]. The DIF-1 protein belongs to the family of
mitochondrial carrier proteins, has 56% identity to the
human carnitine-acylcarnitine translocase, and is thought
to have a role in embryonic energy metabolism. dif-1
homozygotes derived from a heterozygous mother are
completely wild-type. However, the progeny of a homozy-
gous dif-1 hermaphrodite are unable to complete the early
steps of embryogenesis. Likewise, the clk-1 mutation exhib-
its a maternal effect; the slow development and the long-life
phenotypes are only seen in the F2 generation and beyond
[105]. Maternal effects for mitochondrial genes have also
been observed in mice. The losses of TFAM (transcription
factor A, mitochondrial) [106], cytochrome c [107], or CLK-
1 [108] in mice all result in embryonic lethality, although the
earliest steps of development, which are presumably sup-
ported by maternal products, are apparently normal.
3.4. Tissue specificity
The tissue-specificity of mitochondrial diseases has been
attributed to at least two factors: the level of dependence of
a tissue for MRC-generated ATP, and differences in the
levels of heteroplasmy when mtDNA mutations are present
[109]. Perhaps the best studied examples of tissue-specific
mitochondrial effects are with Tfam-deficient mice
[106,110–113], but discussion of these results is beyond
the scope of this review.
The tissue-specificity of an MRC mutation has also been
addressed in the nematode system by utilizing a technique
called mosaic analysis [114,115]. In mosaic animals, some
cells are genotypically wild-type, while others are genotypi-
cally mutant due to the infrequent, spontaneous loss of a
complementing transgenic array introduced by transforma-
tion. The array contains the complementing gene as well as
a gene for a reporter molecule such as the green fluorescent
protein [116]. When the transgenic array is present in a
mutant cell, the cell is fluorescent and is genotypically wild-
type. In the absence of fluorescence, the cell is assumed to
have lost the transgenic array and be genotypically mutant.The mosaic expression of the atp-2 gene has been inves-
tigated [117]. The atp-2(ua2) mutation results in an arrest at
the L3 stage of development, but a complementing trans-
genic array present in all cells renders the animals geno-
typically and phenotypically wild-type. Frequently, the
complete loss of the array occurs and the animals become
identical to atp-2(ua2) mutants. However, rare mosaic
animals with a spontaneous loss of the transgenic array
from certain cell lineages early in development can be
isolated by their incomplete fluorescence patterns. atp-2
mosaic animals with array losses in some of their neuronal,
pharyngeal, or hypodermal cells, or in all their intestinal
cells, can occasionally develop past the L3 stage [117].
Mosaics in which some or all of the body muscle cells have
not inherited the transgenic array invariably result in L3
developmental arrest. Although the array is required by all
tissues for optimal development, transgene function in body
muscle is closely correlated to larval development from the
L3 to the L4 stage. Muscle may rely heavily on the MRC for
energy generation or it may play a pivotal role in devel-
opmental regulation.
Animal development appears to be an all-or-none phe-
nomenon. In any single atp-2 mosaic, either all or none of
the cells or tissues develop past L3, even though a mixture
of genotypically wild-type and mutant cells is present [117].
The atp-2 gene functions in a cell nonautonomous manner;
a one-to-one correspondence between a cell’s genotype and
its phenotype is absent. Cell nonautonomy suggests that
development beyond the L3 stage is controlled by a global
mechanism in which all cells somehow reach a consensus
decision to continue development or not.4. Aging and life span
4.1. Short life span
Several genetic studies indicate that MRC function is
intimately linked to life span determination in C. elegans.
Mitochondria are the major endogenous source of reactive
oxygen species (ROS) such as superoxide anions, hydrogen
peroxide, and hydroxyl radicals [118,119]. Superoxide
anions are constantly generated at low levels by the MRC
and can be converted to hydrogen peroxide by the mito-
chondrial manganese superoxide dismutase. The hydrogen
peroxide can in turn be detoxified to water by glutathione
peroxidase. Reduced metal ions can catalyze the conversion
of hydrogen peroxide to the hydroxyl radical, the most
reactive and damaging of all ROS. The ‘‘free radical theory
of aging’’ proposed by Harman [120] states that increased
respiration will lead to increased ROS production and
damage to cellular lipids, proteins, and nucleic acids.
Oxidative damage inflicted by ROS is believed to be a
determinant of premature aging.
The mev-1(kn1) mutation, a missense allele in the cyt-1
gene encoding the cytochrome b subunit of complex II, was
W.Y. Tsang, B.D. Lemire / Biochimica et Biophysica Acta 1638 (2003) 91–105 101originally isolated in a mutant screen for hypersensitivity to
methyl viologen (paraquat), a compound that increases ROS
production [121]. Hyperoxia is toxic to the mutant; its life
span decreases rapidly with increasing oxygen concentra-
tions [122]. Complex II activity is severely reduced, the
production of lactate and superoxide anions are elevated,
and glutathione content is decreased [123]. mev-1 mutants
accumulate markers indicative of an accelerated rate of
aging such as protein carbonyl derivatives [124,125] and
are hypermutable, especially at higher oxygen concentra-
tions [126]. The mev-1 phenotype has been primarily
attributed to the increased generation of ROS at complex
II, either through the release of electrons directly to oxygen
or through the premature release of ubisemiquinone radicals
[123]. Curiously, ROS scavengers such as EUK-8 and
EUK-134, compounds that exhibit both catalase-like and
superoxide dismutase-like activities, can dramatically
increase the life span of wild-type worms under certain
culture conditions [127]. They can also restore the short-
lived mev-1 mutants to a normal life span, demonstrating
that endogenous mitochondrial ROS production in this
mutant strain is the major cause of accelerated aging
[127]. However, the dramatic results achieved with the
scavengers have been questioned [128]. The role of com-
plex II in mitochondrial energetics and in oxygen sensing
has recently received increased attention with the identifi-
cation of numerous complex II mutations leading to the
development of paragangliomas, tumours in the head and
neck region [129].
The gas-1(fc21) ( general anesthetic sensitive) mutation,
originally isolated in a screen for volatile anesthetic hyper-
sensitivity, affects the 49-kDa subunit of complex I and
profoundly impairs complex I activity [130]. Like the mev-1
mutant, gas-1 animals are also hypersensitive to free radical
damage and hyperoxia, and have a shortened life span
[126,130]. In contrast to the mev-1 mutant, the gas-1 mutant
is not hypermutable and does not overproduce superoxide
anions [126]. GAS-1 is most abundant in mitochondria of
neurons and muscles, the tissues that are most likely to be
the site of action of the anesthetic-induced immobility [131].
The gas-1 mutation likely impairs the proper assembly of
complex I, but how it exerts its effects on life span and
anesthetic sensitivity is still unclear.
4.2. Long life span
MRC mutations can also promote longevity. A mutation
in the isp-1 gene encoding the iron–sulfur protein of
complex III slows embryonic development and doubles
the maximum life span [132]. isp-1 mutants have a reduced
rate of oxygen consumption, indicating that electron trans-
port along the MRC is compromised. A spontaneous partial
suppressor of the slow rate of embryonic development in
isp-1 animals was isolated and determined to be a point
mutation in the mitochondrially encoded cytochrome b
gene. The ctb-1(qm189) suppressor mutation is maternallyinherited, exists in a stable homoplasmic state, and has no
independent phenotype but increases respiration and parti-
ally suppresses the slow behavioral and reproductive fea-
tures without affecting the extended life span of isp-1
animals [132]. The ctb-1 mutation appears to enhance the
low rate of electron transport of the isp-1 mutant. The isp-1,
ctb-1 double mutant displays increased resistance to para-
quat-induced oxidative stress. Mutations in the daf-2 gene,
which affects the dauer pathway, result in an elevated
expression of superoxide dismutase and an increased life
span. daf-2 mutations do not further increase the life span of
the isp-1 mutant, suggesting the increases in life span
operate through a similar pathway or mechanism in both
mutations.
A probable null mutation (lrs-2(mg312)) in the gene
encoding the mitochondrial leucyl-tRNA synthetase mark-
edly extends life span (twofold at 20 jC) [133]. This
synthetase is needed to charge mitochondrial tRNAs for
the translation of the 12 mtDNA-encoded MRC genes.
[133]. Mutants have disorganized, swollen, and sometimes
fused mitochondria, possibly as a result of impaired oxida-
tive phosphorylation. lrs-2 mutants do not arrest develop-
ment but rather develop more slowly into L4-sized, sterile
adults with arrested gonad development. This phenotype
suggests that the mg312 allele does not impair oxidative
phosphorylation to the same extent as other MRC mutations
such as nuo-1(ua1) and atp-2(ua2). The mg312 allele may
not be a null or other synthetases can partially compensate
for the lost activity of the lrs-2 gene product. lrs-2 mutants
are hypersensitive to paraquat, suggesting that the extended
life span is not due to lower mitochondrial ROS production
or to increased defenses against ROS. Rather, the authors
speculate that the compromised mitochondria cause a meta-
bolic shift from respiration towards the glyoxylate cycle as
seen in dauer larvae [36,37].
In a systematic RNAi screen for gene inactivations that
increase life span, genes important for mitochondrial func-
tion formed the most prominent group, accounting for 15%
of all longevity genes [133]. These genes encoded subunits
of the MRC, mitochondrial carrier proteins, a subunit of the
mitochondrial ribosome, and a protein involved in the
biogenesis of the MRC [133]. The RNAi treatments lowered
ATP levels, reduced respiration, and altered organellar
morphologies. For other genes encoding mitochondrial
functions, lethality (L2, L3, or L4 arrest) or sterility was
observed, suggesting that life span extension might result
from more moderate losses of respiratory function [133]. A
second systematic RNAi screen also emphasizes the con-
nection between MRC function and aging [134]. RNAi-
mediated inactivation of the nuo-2, cyc-1 (cytochrome c
reductase), cco-1 (cytochrome c oxidase), and atp-3 genes
encoding subunits of complexes I, III, IV, and V, respec-
tively, extended life span, reduced the size of the adult
without affecting cell number, and reduced ATP levels.
Interestingly, exposure to antimycin A, a complex III
inhibitor which should reduce rates of respiration, also
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only occurred when RNAi treatments were employed during
worm development prior to reaching the adult stage. Fur-
thermore, when cco-1 RNAi treatment imposed throughout
development is removed during adulthood, cco-1 mRNA
content increases to almost normal levels, but this does not
lead to a concurrent restoration of ATP levels. Respiratory
chain activity established earlier during development per-
manently limits ATP production, even when the original
impairment imposed by RNAi treatment is removed. Thus,
C. elegans may possess a regulatory system that sets the rate
of respiration during development and maintains this rate
throughout the animal’s life, thus affecting growth rate,
body size, and life span [134].
Mutations in the clk-1 gene, which encodes a mitochon-
drial protein with a high degree of similarity to yeast Coq7p,
disrupt the biosynthesis of ubiquinone and result in signifi-
cant life span extension [105,135]. Timing is also deregu-
lated in clk-1 mutants; they exhibit a lengthening of
embryonic and post-embryonic development, an extended
cell cycle period, a longer defecation cycle, and reduced
mobility, pharyngeal pumping rates, and brood sizes. Over-
expression of CLK-1 in a wild type background accelerates
aging [136], suggesting that besides quinone synthesis, the
protein regulates developmental and behavioral processes.
In contrast to C. elegans clk-1 mutants, which are healthy,
yeast COQ7 mutants are respiration-deficient [137,138].
How do clk-1 mutants grow and respire with apparently
normal rates of respiration? The answer lies in the culture
conditions; the nematodes are routinely grown on E. coli
and rely on bacterial Q8 [59]. clk-1 mutants are inviable on
ubiquinone-biosynthesis deficient E. coli strains [85]. The
animals no longer exhibit the pleiotropic long-lived pheno-
type, but instead arrest development as larvae or are sterile
when developed from dauer larvae.
Mitochondria from clk-1 animals do not contain detect-
able levels of Q9, the main form of ubiquinone in wild-type
C. elegans, but instead accumulate demethoxy-Q (DMQ9),
an intermediate in Q synthesis [59,139]. The precise role of
DMQ9 in mitochondrial function and in development is
controversial. DMQ9 cannot replace Q9 during develop-
ment; clk-1 animals remain arrested as L2 larvae unless
supplied with a Q-replete diet [59]. Surprisingly, clk-1
mitochondria respire at near normal rates [136,139] and
these findings have been used to postulate a nonrespiratory
developmental role for Q. The levels of another quinone
species, rhodoquinone (RQ9), are also elevated in clk-1
mutants [59,85] and the normal respiration rates may reflect
the use of RQ9 or diet-derived Q8 [59]. RQ9 may also be
important in anaerobic respiration. In parasitic helminths
such as Ascaris suum, RQ9 functions as an electron carrier
between complex I and fumarate reductase, allowing fuma-
rate to serve as the terminal electron acceptor instead of
oxygen [140,141]. Fumarate reductase and succinate dehy-
drogenase or complex II are closely related enzymes that
catalyze the transfer of electrons between succinate/fuma-rate and quinones/quinols, although in opposite directions.
In C. elegans, there are three loci encoding flavoprotein
subunits; two are closely related to succinate dehydro-
genases, while the third is more closely related to fumarate
reductases (Table 1). The presence of RQ9 in clk-1 mito-
chondria raises the possibility that clk-1 mutants may respire
with fumarate as terminal acceptor [142].
How do clk-1 mutations and the resultant alterations in
quinone compositions lead to the observed clk-1 pheno-
type, which includes the increase in life span? The
biochemical data suggest that decreased energy production
may not be responsible for all aspects of the clk phenotype
since clk-1 animals have ATP levels comparable to the
wild type [136,143]. However, the validity of using ATP
levels as an indirect measure of metabolism has been
questioned [144]. Genetic suppressors that accelerate the
slow defecation cycle of clk-1 mutants can do so without
affecting other aspects of the clk phenotype [145,146]. The
existence of these suppressors makes it unlikely that the
clk-1 slow defecation cycle is due to altered quinone
levels; it seems improbable that the suppressors could
restore Q9 synthesis only to the set of cells that controls
the timing of defecation. These observations further sup-
port the hypothesis that CLK-1 or the downstream product
of its action, Q, has an additional role beyond quinone
synthesis and energy production and that the accumulated
DMQ9 intermediate in clk-1 mutants is unable to substitute
for Q in its other physiological functions, which may
include regulatory roles [94,146,147]. Curiously, an eat-2
(eating abnormal) mutation, which disrupts pharyngeal
function and results in a low caloric intake, can increase
life span through the same pathway(s) in which clk-1
works; a clk-1, eat-2 double mutant does not result in
any further extension of life span [148]. Therefore, clk-1
mutations, like caloric restriction, may promote longevity
by lowering metabolic rates and/or the ROS production of
mitochondria. In contrast to the eat-2 situation, the effects
of clk-1 and daf-2 mutations on life span are additive,
suggesting that clk-1 and daf-2 increase longevity via two
different mechanisms; the daf-2 longevity is attributed to
increased stress resistance [149].
The clk-1 mutants suggest that longevity is linked to a
decreased level of Q9. Larsen and Clarke [142] tested the
hypothesis that withdrawal of dietary Q8, the form present in
E. coli, would lead to a prolonged life span and observed a
60% increase in the life span of wild-type worms. The
longevity of daf-2 mutants could also be further increased
on the Q-less diet. They attributed the longer life span of Q
withdrawal and of daf-2 to parallel pathways that converge
in the mitochondrion to reduce the generation of ROS or
increase defenses against them [142]. The electrochemical
properties of DMQ9 may also contribute to life span
extension through a reduced production of ROS in clk-1
mutants [139]. Interestingly, the longevity, but not the slow
phenotypes, of clk-1 mutants is dependent on the presence
of the reproductive system [134]. Ablation of the somatic
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caused by the clk-1 mutation [134].
In addition to isp-1 and clk-1, mutations in three other
genes (gro-1, nuo-1, atp-2) can also lead to an extended
life span. The phenotype of gro-1 (growth rate abnormal)
mutants shares a number of common features with that of
clk-1 including a maternal effect, an increased life span, a
brood size reduction, and deregulated developmental and
behavioral rates [150]. GRO-1 is an enzyme called iso-
pentenylpyrophosphate:tRNA transferase, which functions
to modify a subset of mitochondrial tRNAs and thus could
affect translation of mtDNA encoded genes. gro-1 and clk-
1 interact genetically and thus may act through same
genetic pathway as caloric restriction [149]. Interestingly,
nuo-1 and atp-2 mutants can also live significantly longer
and have reduced mobility, reduced pharyngeal pumping
rate, and a longer defecation cycle [81]. Although these
mutants are lethal when developing from eggs, post-embry-
onic knockdown of atp-2 function by RNAi can slow down
development and lead to a decrease in brood size (W.
Tsang and B. Lemire, unpublished data), suggesting that
longevity may work via the same mechanisms as isp-1, clk-
1, or gro-1.5. Conclusion
Mitochondria are fascinating organelles long recognized
for their role in metabolism but more recently acclaimed for
their pivotal involvement in diseases, apoptosis, organismal
development, and life span determination. Animal models
are invaluable for understanding and elucidating the molec-
ular bases of the pathophysiologies stemming from mito-
chondrial dysfunction. The nematode, C. elegans, has a
particularly prominent place in aging research, but also
more recently in elucidating the still elusive mechanism of
mitochondrial communication with the cellular control cen-
ter in the nucleus. Genes that control mitochondrial attach-
ment, division, and morphology have now been identified in
C. elegans. Elaboration of the factors and processes
involved in mitochondrial biogenesis, maintenance, and
genetics is still an emerging field but the tools and oppor-
tunities furnished by the nematode system promise rapid
progress.
Mitochondria influence and possibly control the rate of
aging. Increased ROS production associated with mitochon-
drial dysfunction can precipitate premature aging and
shorten life span. In contrast, caloric restriction and
increased stress resistance can prolong life span. Integrating
the contributions of ROS production, defense mechanisms
against ROS, respiration rates, and ATP concentrations,
which are all focussed in the mitochondrion, to organismal
health and life span poses a considerable but exciting
challenge. We believe that the nematode system will con-
tinue to generate significant advances in our understanding
of the eucaryotic cellular powerhouse.Acknowledgements
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